- Open Access
Feedback inhibition of L1 and alu retrotransposition through altered double strand break repair kinetics
© Wallace et al; licensee BioMed Central Ltd. 2010
- Received: 3 March 2010
- Accepted: 27 October 2010
- Published: 27 October 2010
Cells adapt to various chronic toxic exposures in a multitude of ways to minimize further damage and maximize their growth potential. Expression of L1 elements in the human genome can be greatly deleterious to cells, generating numerous double strand breaks (DSBs). Cells have been reported to respond to chronic DSBs by altering the repair of these breaks, including increasing the rate of homology independent DSB repair. Retrotransposition is strongly affected by proteins involved in DSB repair. Therefore, L1 expression has the potential to be a source of chronic DSBs and thus bring about the changes in cellular environment that could ultimately restrict its own retrotransposition.
We demonstrate that constitutive L1 expression leads to quicker DSB repair and decreases in the retrotransposition potential of L1 and other retrotransposons dependent on L1 expression for their mobility. This cellular adaptation results in reduced sensitivity to L1 induced toxicity. These effects can be induced by constitutive expression of the functional L1 ORF2 alone, but not by the constitutive expression of an L1 open reading frame 2 with mutations to its endonuclease and reverse transcriptase domains. This adaptation correlates with the relative activity of the L1 introduced into the cells.
The increased number of DSBs resulting from constitutive expression of L1 results in a more rapid rate of repair. The cellular response to this L1 expression also results in attenuation of retrotransposition and reduced sensitivity of the cells to negative consequences of L1 ORF2 expression. The influence does not appear to be through RNA interference. We believe that the increased rate of DSB repair is the most likely cause of the attenuation of retrotransposition. These alterations act as a fail safe mechanism that allows cells to escape the toxicity associated with the unchecked L1 expression. This gives cells that overexpress L1, such as tumor cells, the ability to survive the high levels of expression. However, the increased rate of break repair may come at the cost of accuracy of repair of the lesion, resulting in increased genomic instability.
- Colony Formation Assay
- Ataxia Telangiectasia Mutate
- 53BP1 Focus
- ORF2 mRNA
- Strand Specific Probe
Mammalian cells often evolve adaptive responses to deal with chronic exposure to various toxic agents, including ethanol and opiates [1–4]. Cells also adapt to chronic exposure to sublethal doses of DNA double strand breaks (DSBs) through the selection of cells with altered DSB repair . Typically, mammalian cells depend on a balance between two broad classes of DSB repair to ensure proper genome maintenance. Homologous repair (HR) is a process largely dependent on homology, whereas non-homologous end joining (NHEJ) is mostly independent of homology . Chronic sublethal levels of DSBs cause an altered balance between these two pathways, shifting the balance towards NHEJ .
Long interspersed element-1 (LINE-1 or L1) is the most numerous and only currently active family of human autonomous, non-long terminal repeat (LTR) retrotransposons. They constitute 17% of the genome, with approximately 500,000 copies. Most of these L1 elements do not contain functional copies of the two open reading frames (ORF1 and ORF2) required for efficient retrotransposition [6–8]. Only around 100 L1 elements contain functional copies of both ORFs, which may allow them to contribute to DNA damage and human disease [7, 9].
The L1 ORF2p has been demonstrated to contain both endonuclease and reverse transcriptase activities, which are crucial for retrotransposition [10–12]. These ORF2 domains play essential roles in target primed reverse transcription (TPRT), the proposed mechanism for the retrotransposition of L1 elements [13–15]. This mechanism predicts the transient creation of a DSB at the site of integration.
L1 expression is associated with DSB formation [16, 17], and long term exposure to sublethal levels of DSBs has been associated with alterations in the repair of DNA lesions . Therefore, long term exposure to L1 expression may also alter the response of a cell to DNA damage, which may influence the retrotransposition process. Retrotransposition is strongly affected by several DNA repair proteins, including excision repair cross complementing/xeroderma pigmentosum F (ERCC1/XPF), ataxia telangiectasia mutated (ATM) and p53 [16, 18]. Furthermore, the DSBs caused by L1 have been implicated as a causative agent in creating chromosomal translocations normally associated with cancer , probably through a NHEJ mechanism.
High levels of endogenous full length L1 mRNA expression have been detected in multiple tissues and cell lines . The endogenous expression of this full length L1 mRNA implies that various tissues and cell lines are exposed to chronic expression of L1 ORF2p. The expression of L1, particularly the L1 ORF2p, has been shown to result in substantially decreased cellular proliferation and increased cell death [17, 21]. This toxicity is probably due to induction of DSBs associated with the expression of L1 ORF2p, because a mutation in the endonuclease domain of the L1 ORF2p greatly diminishes the L1-associated toxicity.
Using cells stably expressing both functional and non-functional L1 ORF2p, we show that cells adapt to the constitutive expression of the functional L1 ORF2p in a dose dependent manner, by repressing the retrotransposition of both L1 and Alu. Furthermore, this cellular adaptation, which limits retrotransposition, also diminishes the toxicity typically associated with the expression of L1 ORF2p. We demonstrate that cells exposed to constitutive L1 ORF2p expression have altered DNA DSB repair kinetics, which provides a potential explanation for the reduction of L1 and Alu mobilization, and the diminished toxicity associated with L1 expression.
Constitutive L1 expression results in reduced retrotransposition
To test the effect of constitutive L1 expression on retrotransposition, we measured the retrotransposition of tagged L1  and Alu  elements. Alu and L1 retrotransposition in both HCT116 and HeLa cells stably expressing L1 ORF2 (HeLa ORF2, HCT116 ORF2) were significantly (P ≤ 0.05) lower than in corresponding control cells (HeLa ORF2 ER--, HCT luciferase) (Figure 2). The magnitude of repression of retrotransposition was generally greater for Alu elements than for L1 elements. Because the ORF2p level in the stable cell lines is expected to be relatively low compared with transient transfection assays and also should be variable between the various groups of cells, we cotransfected the cells with either ORF2 or full length L1 to provide relatively similar levels of ORF2 in the various cell lines to drive the retrotransposition of the tagged Alu element. The difference in the decrease in Alu retrotransposition was unaltered when Alu retrotransposition was driven by either a full length L1 or an L1 ORF2 (see Additional file 2). Decreased retrotransposition was also similar in cells stably expressing either a full length L1 element or the L1 ORF2 (Figure 2).
To determine whether increased L1 expression would result in a more pronounced phenotype, we generated HeLa cells that stably express a synthetic version of L1 that had been codon optimized to increase expression of the element (HeLa Optimized L1) (See Wallace et al. for further description). When Alu and L1 retrotransposition in these cells was measured, both Alu and L1 retrotransposition were almost completely suppressed (Figure 2).
Constitutive L1 expression results in reduced sensitivity to toxicity associated with transient L1 expression
The transient expression of L1, and particularly L1 ORF2, is very toxic, resulting in the reduction of cellular proliferation, and induction of apoptosis and cellular senescence [16, 17, 21]. It is possible that HeLa ORF2 cells had a higher sensitivity to transient expression of L1 ORF2, which could explain the reduced retrotransposition in these cells. To explore this possibility, we measured the toxicity associated with transient L1 expression using a previously described colony formation assay . Expression of either L1 or L1 ORF2 resulted in significantly(P ≤ 0.05) fewer G418 resistant colonies in HeLa ORF2 ER-- cells than in HeLa ORF2 cells (Figure 3B). This indicates that increased sensitivity to transient L1 expression cannot explain the differences in retrotransposition potential between the two cell lines. Indeed, cells stably expressing L1 ORF2 were more resistant to L1 toxicity.
To determine whether cells constitutively expressing L1 ORF2 were less sensitive to DSBs in general, we measured the toxicity of ionizing radiation (IR) induced DSBs on HeLa ORF2 and HeLa ORF2 ER-- cells. Significantly different sensitivity to IR between these cell lines was not found in either a proliferation or a colony formation assay (Figure 3C, Additional File 3).
Together, these data suggest that the reduced retrotransposition rates observed in the long term L1 expressing cells are not due to an impaired growth rate, and additionally cannot easily be explained by differences in the viability or general health of the cells. The cells seem to have adapted to the stable expression of L1 ORF2 by specifically diminishing their sensitivity to L1 ORF2 as a source of DSBs.
Repression of retrotransposition is not through RNA interference
Constitutive L1 ORF2 expression results in alterations in DSB repair kinetics
Cells adapt to constitutive expression of LINE-1 by repressing Alu and L1 retrotransposition
Human cells adapt to chronic expression of functional L1 elements, specifically the L1 ORF2, in a dose dependent manner. This adaptation includes strong suppression of the retrotransposition potential of both L1 and Alu elements (Figure 2). This is consistent with our observation that retrotransposition was inversely proportional to endogenous L1 expression in cell lines with varying levels of endogenous expression of L1 (Figure 1). It has been found that retrotransposition of human mobile elements is suppressed by a plethora of mechanisms, including DNA methylation, transcription regulation, RNA processing, APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like) proteins and DNA repair pathways [18, 23, 31–36]. The abundance of methods used to silence these elements is probably necessary because of their high copy number, but also reflects the importance of effective inhibition in almost all cell types and developmental situations. This newly discovered feedback inhibition of L1 ORF2 activity provides a fail safe method of reducing the deleterious effects of L1 ORF2 expression.
It is possible that, although it minimizes retrotransposition and direct cellular toxicity, the rapid repair of the DSBs may lead to error prone repair processes. The cellular response to chronic DSBs is to increase NHEJ repair of lesions and hence more rapidly mend the break. Cells exposed to chronic low levels of DSBs induced by L1 also respond by increasing the rate of DSB repair, mostly likely also by increasing NHEJ . Whereas homology independent repair would eliminate the immediate toxic effects of L1 expression, NHEJ is an error prone process that could lead to in increased mutation rate in cells.
Mechanism of retrotransposition repression by chronic L1 expression
Initially we considered that reduction of retrotransposition might be through an RNAi-like mechanism that responded to the expression of the L1 RNA. However, we dismissed this possibility because the chronic expression of L1 was able to repress Alu retrotransposition, even when an ORF2 with altered nucleotide sequence was used to drive the Alu. More importantly, expression of an inactive L1 ORF2, with only a few point mutations, did not show the same repression (ORF2 ER--). Because the RNA from the mutant ORF2 should only differ by two bases from the wild type RNA, it is very unlikely that it would influence RNAi differentially.
Our data indicate that the most likely mechanism of repression of retrotransposition in our system is a response induced by the DNA DSBs caused by the L1 endonuclease. Constitutive expression of the L1 endonuclease is analogous to the exposure to chronic DSBs, which results in more rapid DSB repair . Although these cells had an altered DNA damage response, they were not more sensitive to ionizing radiation and did not have altered growth rates, just as we detected in response to chronic L1 treatment (Figure 2B). The most notable changes in response to chronic L1 treatment, other than repression of retrotransposition, was that the cells had a significantly (P ≤ 0.05) faster repair of DSBs and greater protection from toxicity associated with transient ORF2p expression (Figure 5). Thus, we speculate that stimulation of DNA repair allows the cell to clear nascent L1 insertion events before they can complete insertion, much like that demonstrated for the ERCC1/XPF endonuclease . Similarly, it has been suggested that NHEJ proteins limit L1 retrotransposition events by rapidly repairing the L1 generated DSB before the L1 cDNA can be integrated into the break .
We found a significant (P ≤ 0.05) increase in DNA repair associated with a decrease in retrotransposition. The change in DSB repair timing was measured by the formation and clearance of 53BP1 foci. 53BP1 foci format DSBs and are associated with NHEJ mediated repair of these lesions . Because of this association, our data imply an increase in NHEJ repair specifically. Therefore, a likely mechanism for our observed feedback inhibition of retrotransposition is that chronic L1 ORF2 expression induces higher levels of NHEJ that restrict retrotransposition.
We showed that constitutive L1 expression could induce a cellular adaptation that results in more rapid repair of DSBs and repression of retrotransposition. Because it has been suggested that an increase in DSB repair kinetics would decrease retrotransposition, we propose that these two adaptations are related. It is likely that cells adapt to chronic L1 expression by increasing the kinetics of DSB repair, which inhibits retrotransposition. This work highlights the intimate relationship between retrotransposition and DSB repair. In addition, we demonstrate a novel method of cellular adaptation utilized to diminish the toxicity associated with L1 activity.
We combined the contents of four 75 cm2 cell culture flasks of each cell type and extracted total mRNA (TRIzol Reagent, Invitrogen, Carlsbad, CA, USA). We then carried out chloroform extraction and isopropanol precipitation. We selected poly(A) RNA species using a commercial kit (PolyATract mRNA Isolation System III; Promega, Sunnyvale, CA, USA) as instructed by the manufacturer. We resuspended the poly(A) selections and precipitated RNA in 30 μl of RNase-free water and fractionated it in a single lane of agarose formaldehyde gel.
We transferred RNA to a nylon membrane (Hybond-N; Amersham Pharmacia Biotech, Piscatawy, NJ, USA) by capillary transfer overnight at room temperature in a standard 5× sodium chloride/sodium citrate (SSC) solution. We crosslinked the RNA to the membrane with ultraviolet light and prehybridized it in 30% formamide, 1x Denhardt's solution, 1% SDS, 1 mol/l NaCl, 100 μg/ml salmon sperm DNA and 100 μg/ml yeast tRNA at 60°C for at least 6 hours. Hybridization with a strand specific probe was carried out overnight in the same solution at 60°C. We carried out several 10-minute washes at high stringency (0.1x SSC, 0.1% SDS) at 60°C.
We generated (MAXIscript T7 system; Ambion Inc. Austin, TX, USA) the strand specific probe used for the northern blot assay. Primer sequences for generating the template are available on request.
Transient L1  or Alu  retrotransposition assays were performed as previously described with some minor modifications. Briefly, cells were seeded into T-75 flasks at a density of 5 × 105 cells per flask. Transient transfections were performed the next day (Lipofectamine and Plus cocktail; Invitrogen), in accordance with the manufacturer's protocol. Cells were grown under selection media containing 400 μg/ml G418 (Geneticin; Fisher Scientific, Pittsburgh, PA, USA) for 14 days. Colonies were fixed, stained and visually scored.
53bp1 foci visualization
Cells were plated onto a 96 well imaging plate 16 hours before visualization, and treated with 3.7% formaldehyde followed by 90% cold methanol. After washing, cells were blocked with 1% bovine serum albumin, before being incubated with 2 μg/ml of a 53bp1 antibody (Novus Biologicals, Littleton, CO, USA) for 1 hour. Cells were incubated with 5 μg/ml Alexa 488 conjugated secondary antibodies (Molecular Probes, Eugene, OR, USA) and 5 μg/ml Hoechst stain (Molecular Probes) before being visualized.
ORF2 western blots
HeLa cells stably integrated with the L1 constructs were grown to confluence in T75 flasks. Cells were treated with trypsin and pelleted at 300 g, washed twice with phosphate-buffered saline (PBS), and finally resuspended in 400 uL of PBS. Cells were lysed with an equal volume of 2× Laemmli buffer and boiled for 5 minutes. Extracts were fractionated on a 3 to 8% Tris-acetate gel (Invitrogen) and transferred to nitrocellulose membranes(iBlot System; Invitrogen). Membranes were blocked for 1 hour in 5% milk in PBS-Tween and incubated with α-ORF2 antibody (S19, Santa Cruz Biotechnology) overnight at 4°C. Detection was carried out using horseradish peroxidase conjugated secondary antibodies (Santa Cruz Biotechnology) and a substrate kit (SuperSignal West Femto Maximum Sensitivity Substrate Kit; Thermo Scientific, Waltham, MA, USA). Membranes were exposed to BioMax Light Film (Kodak) and developed with a processor (Kodak X-OMAT 2000A; Rochester, NY, USA). Equal loading was confirmed using β-actin antibodies (Sigma Chemical Co., St Louis, MO, USA) using the same protocol.
Growth rate was measured as previously described  with minor alterations. Briefly, cells were seeded into T-75 flasks at a density of 5 × 105 cells per flask. After 1, 2 or 3 days of growth, the cells were collected by trypsinization and quantified using a hemocytometer.
Colony formation assay
Colony formation assays were performed as previously described  with some minor modifications. Briefly, cells were seeded into T-75 flasks at a density of 5 × 105 cells per flask. Transient transfections of a neomycin resistance plasmid were performed the next day (Lipofectamine and Plus cocktail; Invitrogen) in accordance with the manufacturer's protocol. Cells were grown under selection media containing 400 μg/ml Geneticin (Fisher Scientific) for 14 days. Colonies were fixed, stained and visually scored.
Ionizing radiation colony formation assay
After exposure to ionizing radiation, a colony formation assay was conducted as described both above and in previous works .
Ionizing radiation cellular proliferation assay
After ionizing radiation exposure, the cell growth assay described above was conducted, with the minor alteration that cell growth was measured after 7 days instead of 1 to 3 days.
Vectors and sequences
All expression vectors used to generate stable cell lines and to drive Alu retrotransposition (including L1 ORF2 A, B and C) were cloned into the pBud CE 4.1 vector by ligation after digestion with Bam HI and Hin DIII.
The ORF1 sequence of the L1 optimized for expression has previously been described . The L1 ORF2 used in this vector has had synonymous codons replaced with codons of maximum translational efficiency, using a Codon Adaptation Index calculator (http://www.evolvingcode.net) in a manner that preserved the amino acid sequence of the protein.
In all cases, p-values were determined using the student t-test to compare values to the control for each experiment.
We thank Dr Astrid Roy-Engel for providing 7SLneo and U6neo expression vectors. This work was made possible by Grants Number P20RR020152 (PLD and VPB), R01GM45668 (PLD) and a NSF Cooperative Agreement in collaboration with the Louisiana BORSF Support Fund (PLD). NAW received funding from LEQSF (2003-08)-GF-25. VPB receives funding from NIH/KO1 1K01AG030074-01A1 and the Ellison Medical Foundation.
- Delacote F, Deriano L, Lambert S, Bertrand P, Saintigny Y, Lopez BS: Chronic exposure to sublethal doses of radiation mimetic Zeocin selects for clones deficient in homologous recombination. Mutat Res. 2007, 615: 125-133.View ArticlePubMedGoogle Scholar
- Vagts AJ, He DY, Yaka R, Ron D: Cellular adaptation to chronic ethanol results in altered compartmentalization and function of the scaffolding protein RACK1. Alcohol Clin Exp Res. 2003, 27: 1599-1605. 10.1097/01.ALC.0000089957.63597.A4.View ArticlePubMedGoogle Scholar
- Nevo I, Avidor-Reiss T, Levy R, Bayewitch M, Heldman E, Vogel Z: Regulation of adenylyl cyclase isozymes on acute and chronic activation of inhibitory receptors. Mol Pharmacol. 1998, 54: 419-426.PubMedGoogle Scholar
- Mackler SA, Kleyman TR, Cha XY: Regulation of the Na+/K(+)-ATPase pump in vitro after long-term exposure to cocaine: role of serotonin. J Pharmacol Exp Ther. 1998, 285: 835-843.PubMedGoogle Scholar
- Paques F, Haber JE: Multiple pathways of recombination induced by double-strand breaks in Saccharomyces cerevisiae. Microbiol Mol Biol Rev. 1999, 63: 349-404.PubMed CentralPubMedGoogle Scholar
- Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W: Initial sequencing and analysis of the human genome. International Human Genome Sequencing Consortium. Nature. 2001, 409: 860-921. 10.1038/35057062.View ArticlePubMedGoogle Scholar
- Brouha B, Schustak J, Badge RM, Lutz-Prigge S, Farley AH, Moran JV, Kazazian HH: Hot L1s account for the bulk of retrotransposition in the human population. Proc Natl Acad Sci USA. 2003, 100: 5280-5285. 10.1073/pnas.0831042100.PubMed CentralView ArticlePubMedGoogle Scholar
- Penzkofer T, Dandekar T, Zemojtel T: L1Base: from functional annotation to prediction of active LINE-1 elements. Nucleic Acids Res. 2005, 33: D498-500. 10.1093/nar/gki044.PubMed CentralView ArticlePubMedGoogle Scholar
- Seleme Mdel C, Vetter MR, Cordaux R, Bastone L, Batzer MA, Kazazian HH: Extensive individual variation in L1 retrotransposition capability contributes to human genetic diversity. Proc Natl Acad Sci USA. 2006, 103: 6611-6616. 10.1073/pnas.0601324103.View ArticleGoogle Scholar
- Mathias SL, Scott AF, Kazazian HH, Boeke JD, Gabriel A: Reverse transcriptase encoded by a human transposable element. Science. 1991, 254: 1808-1810. 10.1126/science.1722352.View ArticlePubMedGoogle Scholar
- Feng Q, Moran JV, Kazazian Hh, Boeke JD: Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition. Cell. 1996, 87: 905-916. 10.1016/S0092-8674(00)81997-2.View ArticlePubMedGoogle Scholar
- Moran JV, Holmes SE, Naas TP, DeBerardinis RJ, Boeke JD, Kazazian HH: High frequency retrotransposition in cultured mammalian cells. Cell. 1996, 87: 917-927. 10.1016/S0092-8674(00)81998-4.View ArticlePubMedGoogle Scholar
- Luan DD, Korman MH, Jakubczak JL, Eickbush TH: Reverse transcription of R2Bm RNA is primed by a nick at the chromosomal target site: a mechanism for non-LTR retrotransposition. Cell. 1993, 72: 595-605. 10.1016/0092-8674(93)90078-5.View ArticlePubMedGoogle Scholar
- Luan DD, Eickbush TH: RNA template requirements for target DNA-primed reverse transcription by the R2 retrotransposable element. MolCell Biol. 1995, 15: 3882-3891.Google Scholar
- Cost GJ, Feng Q, Jacquier A, Boeke JD: Human L1 element target-primed reverse transcription in vitro. EMBO J. 2002, 21: 5899-5910. 10.1093/emboj/cdf592.PubMed CentralView ArticlePubMedGoogle Scholar
- Gasior SL, Wakeman TP, Xu B, Deininger PL: The human LINE-1 retrotransposon creates DNA double-strand breaks. J Mol Biol. 2006, 357: 1383-93. 10.1016/j.jmb.2006.01.089.PubMed CentralView ArticlePubMedGoogle Scholar
- Belgnaoui SM, Gosden RG, Semmes OJ, Haoudi A: Human LINE-1 retrotransposon induces DNA damage and apoptosis in cancer cells. Cancer Cell Int. 2006, 6: 13-10.1186/1475-2867-6-13.PubMed CentralView ArticlePubMedGoogle Scholar
- Gasior SL, Roy-Engel AM, Deininger PL: ERCC1/XPF limits L1 retrotransposition. DNA Repair (Amst). 2008, 7: 983-989. 10.1016/j.dnarep.2008.02.006.View ArticleGoogle Scholar
- Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, Zhang J, Rose DW, Fu XD, Glass CK, Rosenfeld MG: Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell. 2009, 139: 1069-1083. 10.1016/j.cell.2009.11.030.PubMed CentralView ArticlePubMedGoogle Scholar
- Belancio VP, Roy-Engel AM, Pochampally RR, Deininger P: Somatic expression of LINE-1 elements in human tissues. NucAcids Res. 2010, 38: 3909-22. 10.1093/nar/gkq132.Google Scholar
- Wallace NA, Belancio VP, Deininger PL: L1 mobile element expression causes multiple types of toxicity. Gene. 2008, 419: 75-81. 10.1016/j.gene.2008.04.013.PubMed CentralView ArticlePubMedGoogle Scholar
- Belancio VP, Hedges DJ, Deininger P: LINE-1 RNA splicing and influences on mammalian gene expression. Nucleic Acids Res. 2006, 34: 1512-1521. 10.1093/nar/gkl027.PubMed CentralView ArticlePubMedGoogle Scholar
- Perepelitsa-Belancio V, Deininger P: RNA truncation by premature polyadenylation attenuates human mobile element activity. NatGenet. 2003, 35-Google Scholar
- Rappold I, Iwabuchi K, Date T, Chen J: Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways. J Cell Biol. 2001, 153: 613-620. 10.1083/jcb.153.3.613.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang B, Matsuoka S, Carpenter PB, Elledge SJ: 53BP1, a mediator of the DNA damage checkpoint. Science. 2002, 298: 1435-1438. 10.1126/science.1076182.View ArticlePubMedGoogle Scholar
- Dewannieux M, Esnault C, Heidmann T: LINE-mediated retrotransposition of marked Alu sequences. NatGenet. 2003, 35: 41-48.Google Scholar
- Yang N, Zhang L, Kazazian HH: L1 retrotransposon-mediated stable gene silencing. Nucleic Acids Res. 2005, 33: e57-10.1093/nar/gni056.PubMed CentralView ArticlePubMedGoogle Scholar
- Soifer HS: Do Small RNAs Interfere With LINE-1?. J Biomed Biotechnol. 2006, 2006: 92904-View ArticleGoogle Scholar
- Soifer HS, Zaragoza A, Peyvan M, Behlke MA, Rossi JJ: A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon. Nucleic Acids Res. 2005, 33: 846-856. 10.1093/nar/gki223.PubMed CentralView ArticlePubMedGoogle Scholar
- Aravin AA, Sachidanandam R, Girard A, Fejes-Toth K, Hannon GJ: Developmentally regulated piRNA clusters implicate MILI in transposon control. Science. 2007, 316: 744-747. 10.1126/science.1142612.View ArticlePubMedGoogle Scholar
- Yoder JA, Walsh CP, Bestor TH: Cytosine methylation and the ecology of intragenomic parasites. Trends Genet. 1997, 13: 335-340. 10.1016/S0168-9525(97)01181-5.View ArticlePubMedGoogle Scholar
- Yu F, Zingler N, Schumann G, Stratling WH: Methyl-CpG-binding protein 2 represses LINE-1 expression and retrotransposition but not Alu transcription. Nucleic Acids Res. 2001, 29: 4493-4501. 10.1093/nar/29.21.4493.PubMed CentralView ArticlePubMedGoogle Scholar
- Athanikar JN, Badge RM, Moran JV: A YY1-binding site is required for accurate human LINE-1 transcription initiation. Nucleic Acids Res. 2004, 32: 3846-3855. 10.1093/nar/gkh698.PubMed CentralView ArticlePubMedGoogle Scholar
- Belancio VP, Roy-Engel AM, Deininger P: The impact of multiple splice sites in human L1 elements. Gene. 2008, 411: 38-45. 10.1016/j.gene.2007.12.022.PubMed CentralView ArticlePubMedGoogle Scholar
- Hulme AE, Bogerd HP, Cullen BR, Moran JV: Selective inhibition of Alu retrotransposition by APOBEC3G. Gene. 2007, 390: 199-205. 10.1016/j.gene.2006.08.032.PubMed CentralView ArticlePubMedGoogle Scholar
- Bogerd HP, Wiegand HL, Hulme AE, Garcia-Perez JL, O'Shea KS, Moran JV, Cullen BR: Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc Natl Acad Sci USA. 2006, 103: 8780-8785. 10.1073/pnas.0603313103.PubMed CentralView ArticlePubMedGoogle Scholar
- Hata K, Sakaki Y: Identification of critical CpG sites for repression of L1 transcription by DNA methylation. Gene. 1997, 189: 227-234. 10.1016/S0378-1119(96)00856-6.View ArticlePubMedGoogle Scholar
- Roman-Gomez J, Jimenez-Velasco A, Agirre X, Cervantes F, Sanchez J, Garate L, Barrios M, Castillejo JA, Navarro G, Colomer D, Prosper F, Heiniger A, Torres A: Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene. 2005, 24: 7213-7223. 10.1038/sj.onc.1208866.View ArticlePubMedGoogle Scholar
- Feinberg AP: The epigenetics of cancer etiology. Semin Cancer Biol. 2004, 14: 427-432. 10.1016/j.semcancer.2004.06.005.View ArticlePubMedGoogle Scholar
- Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983, 301: 89-92. 10.1038/301089a0.View ArticlePubMedGoogle Scholar
- Ehrlich M: Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr Top Microbiol Immunol. 2006, 310: 251-274. full_text.PubMedGoogle Scholar
- Suzuki J, Yamaguchi K, Kajikawa M, Ichiyanagi K, Adachi N, Koyama H, Takeda S, Okada N: Genetic evidence that the non-homologous end-joining repair pathway is involved in LINE retrotransposition. PLoS Genet. 2009, 5: e1000461-10.1371/journal.pgen.1000461.PubMed CentralView ArticlePubMedGoogle Scholar
- Adams MM, Carpenter PB: Tying the loose ends together in DNA double strand break repair with 53BP1. Cell Div. 2006, 1: 19-10.1186/1747-1028-1-19.PubMed CentralView ArticlePubMedGoogle Scholar
- Wallace N, Wagstaff BJ, Deininger PL, Roy-Engel AM: LINE-1 ORF1 protein enhances Alu SINE retrotransposition. Gene. 2008, 419: 1-6. 10.1016/j.gene.2008.04.007.PubMed CentralView ArticlePubMedGoogle Scholar
- Comeaux MS, Roy-Engel AM, Hedges DJ, Deininger PL: Diverse cis factors controlling Alu retrotransposition: what causes Alu elements to die?. Genome Res. 2009, 19: 545-555. 10.1101/gr.089789.108.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.